CIC DUX4 FISH
Also known as: t(4;19) FISH, Ewing-like sarcoma FISH, undifferentiated small blue round cell sarcoma FISH, primitive round cell sarcoma FISH
Oncology - Sarcoma
Use of test
The CIC gene at 19q13.2 has been found to be fused with the DUX4 gene at 4q35.2 in a sub-group of Ewing like sarcomas. Testing with this FISH probe determines whether breakage of CIC has occurred, consistent with the presence of the rearrangement.
This test has diagnostic implications.
This is an assay for non-heritable mutations. It does not raise issues of ethics or consent that are different from most other investigations ordered in the routine care of a patient.
Fluorescent in situ hybridisation (FISH) analysis, using probes to detect breakage of the CIC gene. This test is performed on thin sections of tissue, so some cells in the section may be sliced by the process, and only contain some of the regions of interest. Sections may contain bony, fatty or necrotic material, which may interfere with processing and/or analysis. Dense tissue also makes identification of individual cells difficult. The accuracy of the results is dependent on the correct identification of tumour on the sections provided, and the assumption that positive results will be identified by a large proportion of cells within the tumour having a rearrangement.
Requesting the test
This test is usually requested by an oncologist.
Download the somatic mutation request form.
Formalin-fixed, paraffin embedded tissue (FFPE) - 15 sections of 4 uM thickness, dried overnight at 37°C onto charged/coated slides.
Please stain the first section with H&E, and label each slide with patient and block identifiers. Label the unstained sections sequentially (slides 2-15). The request should be accompanied by the somatic mutation request form (above) and a copy of the original histopathology report.
5 business days.
Up to $410.
If more information is required, the requesting clinician can call our laboratory on (07) 3377 8573.
This test is not rebated by Medicare. The laboratory assumes that the patient or client has provided informed financial consent for the test.